MTS-105

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameMTS-105
Drug Alias NameMTS105MTS-105Mts105
ClassificationCell and gene therapy > Gene therapy > mRNACell and gene therapy > Gene therapy > LNPBiologics > T cell engagers +[5] 
Mechanisms of ActionAnti-CD3Glypican-3 modulators
TargetsT cell surface glycoprotein CD3Glypican-3
Therapy Area/IndicationsLiver NeoplasmsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMETiS Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesMETiS Pharmaceuticals
Inactive CompaniesN/A
Active IndicationsLiver NeoplasmsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A